Compare CVS Health Corp (CVS) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Wahed FTSE USA Shariah ETF — how do they compare? CVS Health Corp trades at $94.35 (market cap $119.58B), while Wahed FTSE USA Shariah ETF trades at $72.95. The key difference: CVS Health Corp pays a 2.84% dividend while Wahed FTSE USA Shariah ETF pays none, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, CVS Health Corp nearer its low. Which is the better fit depends on your goals.
| CVS | HLAL | |
|---|---|---|
Market Cap | $119.58B | — |
Sector | Health | Sector/Thematic |
52-Week High | $110.60 | $73.60 |
52-Week Low | $65.51 | $55.52 |
Enterprise Value | $181.93B | — |
Dividend Yield | 2.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $94.12, down 1.62% today, but maintains strong analyst support with 33 buy ratings and a $115.90 consensus price target. The company delivered three consecutive earnings beats in 2026, with Q2 EPS of $2.58 beating expectations by 38%. Technical indicators show mixed signals with bullish oscillators but bearish moving averages, while fundamentals reveal solid revenue growth to $402.07B in 2025 despite margin compression.
CVS presents a compelling value opportunity with attractive valuation ratios (P/S: 0.29, P/B: 1.5) and strong institutional confidence. Near-term catalysts include continued Aetna recovery and healthcare services expansion, though risks include 2027 PBM pressures and margin volatility. The stock offers 23% upside to analyst targets with defensive healthcare positioning.
HLAL trades at $73.11 with a slight 0.19% daily gain, showing bullish technical momentum with strong moving average support. The stock lacks key valuation metrics (P/E, P/S, P/B) in current data, and a small dividend of $0.02 is scheduled for June 2026. Technical indicators show mixed signals with RSI suggesting potential overbought conditions near-term.
The outlook remains cautiously optimistic given bullish technical trends, but limited fundamental data and high RSI levels near 95 warrant monitoring. Key risks include reliance on technical momentum without clear valuation anchors, while institutional sentiment appears constructive based on moving average alignment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →
